Evidence map›Paper›PMID 31009585›Full record

ReviewCirculation2019

Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.

Motoaki Sano, Shinichi Goto

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Circulation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07025629 (Dapagliflozin for Cardio-renal Protection After ICU Discharge), which is not on this map. Cited by 134 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07025629 phase3recruitingstarted 2025, after this paper: background citation

Dapagliflozin for Cardio-renal Protection After ICU Discharge: A Prospective, Randomized, Double Blinded, Multicenter Study: "DAPA-ICU Trial"

Ran2025Enrolled600Registered outcomes19Posted comparisons0ConditionsHeart Failure and Chronic Kidney Disease Post-ICUArmsDapagliflozin 10 MG Oral Tablet [Farxiga], One tablet of placebo of dapagliflozin 10 mg
PMID 30424892PMID 32877652PMID 32516543PMID 32492305PMID 30045823PMID 29347987PMID 27391020other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Motoaki SanoDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Shinichi GotoDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HematocritAdenosine TriphosphateCell HypoxiaDiabetes Mellitus, Type 2Diabetic CardiomyopathiesDiabetic NephropathiesDisease ProgressionDiuresisErythropoiesisErythropoietinGene Expression RegulationGlucoseHeartHeart FailureHemoglobinsHumansAdenosine TriphosphateEPO protein, humanErythropoietinGlucoseHemoglobinsSodium-Glucose Transporter 2 InhibitorsSodium-Potassium-Exchanging ATPasecell transdifferentiationheart failurehematocrithypoxiasodium-potassium pumpsympathetic nervous system

Identifiers

PMID31009585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.